Responsibilities
Scientific Coordinator for the IRTG
Contact
Medizinische Klinik und Poliklinik III
Ludwig-Maximilians-Universtiät München
Marchioninistr.15
81377 München
Laboratory Address:
Gene Center
LMU Munich
Feodor-Lynen-Str. 25
81377 München
Phone:
+49 (0)89 44007-3133 (hospital), +49( 0)89 2180 76875 (lab)
Email:
marion.subklewe@med.uni-muenchen.de
Website:
Poliklinik III: AML/MDS Immuntherapy
Website:
Laboratory for Translational Cancer Immunology, Gene Center Munich
Work group
A10 Identifying and targeting escape mechanisms in AML using multispecific antibody derivatives
10 Major publications related to project
(See publications for recent papers published in the SFB context since 2016)
Köhnke T, Sauter D, Ringel K, Hoster E, Laubender RP, Hubmann M, Bohlander SK, Kakadia PM, Schneider S, Dufour A, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Spiekermann K and Subklewe M (2015). Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse. Leukemia 29, 828-38.
Vick B, Rothenberg M, Sandhöfer N, Carlet M, Finkenzeller C, Krupka C, Grunert M, Trumpp A, Corbacioglu S, Ebinger M, André MC, Hiddemann W, Schneider S, Subklewe M, Metzeler KH, Spiekermann K and Jeremias I (2015). An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging. PLoS One,10, e0120925.
Hubmann M, Köhnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, Fiegl M, Braess J, Bohlander SK, Subklewe M, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Hiddemann W and Spiekermann K (2014). Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse. Haematologica, 99, 1317-25.
Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T, Lichtenegger FS, Schneider S, Metzeler K, Fiegl M, Spiekermann K, Baeuerle PA, Hiddemann W, Riethmüller G and Subklewe M (2014). Evaluation of CD33 Expression and Functional Analysis of the CD33/CD3 bispecific BITE Antibody AMG 330 Activity in primary AML samples. Blood, 123, 356-65.
Lichtenegger FS, Lorenz R, Gellhaus K, Hiddemann W, Beck B and Subklewe M (2014). Impaired NK cells and increased T regulatory cell numbers during cytotoxic maintenance therapy in AML. Leuk. Res, 38, 964-969.
Anger A, Amache JP, Berninghausen O, Habeck M, Subklewe M, Wilson D and Beckmann R (2013). Structures of the human and Drosophila 80S ribosome. Nature, 497, 80-85.
Lichtenegger F, Mueller K, Otte B, Beck B, Hiddemann W, Schendel DJ and Subklewe M (2012). CD86 and IL-12p70 Are Key Players for T Helper 1 Polarization and Natural Killer Cell Activation by Toll-Like Receptor-Induced Dendritic Cells. PLoS One, 7, e44266.
Beck B, Dörfel D, Lichtenegger FS, Geiger C, Lindner L, Merk M, Schendel DJ and Subklewe M (2011). Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remision. J Transl Med, 9, 151.
Sebelin K, Schulzki A, Kloetzel PM, Dörken B, Pezzutto A and Subklewe M (2006). Impairment of circulating myeloid dendritic cells in immunosuppressed renal/pancreas transplant recipients. Transplantation, 82, 779-87.
Subklewe M, Paludan C, Tsang LM, Mahnke K, Steinman RM and Munz C (2001). Dendritic cells cross-present latency gene products from Epstein-Barr Virus transformed B cells and expand tumor-reactive CD8+ killer T cells. J Exp Med, 193, 405-411.